330786-09-9

Basic information

• Product Name: METHYL 3,5-DICHLOROPYRAZINE-2-CARBOXYLATE
• Synonyms: METHYL 3,5-DICHLOROPYRAZINE-2-CARBOXYLATE;Pyrazinecarboxylic acid, 3,5-dichloro-, Methyl ester;3,5-Dichloro-pyrazine-2-carboxylic acid Methyl ester;2-Methoxycarbonyl-3,5-dichloropyrazine
• CAS NO: 330786-09-9
• Molecular Formula: C₆H₄Cl₂N₂O₂
• Molecular Weight: 207.01
• Mol File: 330786-09-9.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 269.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.503±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -5.96±0.10(Predicted)
• CAS DataBase Reference: METHYL 3,5-DICHLOROPYRAZINE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3,5-DICHLOROPYRAZINE-2-CARBOXYLATE(330786-09-9)
• EPA Substance Registry System: METHYL 3,5-DICHLOROPYRAZINE-2-CARBOXYLATE(330786-09-9)

Safety Data

• Hazardous Substances Data: 330786-09-9(Hazardous Substances Data)

Usage

General Description

Methyl 3,5-dichloropyrazine-2-carboxylate is a type of chemical compound that falls under the class of Pyrazines, compounds with a pyrazine ring, a six-membered aromatic heterocycle with two nitrogen atoms replacing two carbon atoms at opposite positions. Its structured release mostly occurs from product manufacturing or use such as manufacturer's effluents and household chemicals. Given its chemical structure, it is used primarily in the research and pharmaceutical industries. Its potential risks and impacts are largely unknown due to the relative novelty of this compound and there are currently no specific guidelines or recommendations about its potential toxicity or safe exposure levels.

Upstream product

• 312736-49-5 3,5-dichloropyrazine-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 124-38-9 carbon dioxide 
• 4774-14-5 2,6-dichloropyrazine 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 1430460-79-9 methyl 5-(benzylamino)-3-chloropyrazine-2-carboxylate 
• 1430460-64-2 methyl 3-(benzylamino)-5-chloropyrazine-2-carboxylate 
• 1438419-70-5 3-(4-(4-acetylpiperazin-1-yl)phenylamino)-5-(cyclopropylamino)pyrazine-2-carboxamide 
• 1438419-29-4 5-((1R,2S)-2-aminocyclohexylamino)-3-(1-methyl-1H-indol-4-ylamino)pyrazine-2-carboxylic acid amide 
• 1610853-06-9 N-[(4-chlorophenyl)-methyl]-3-isopropyl-5-morpholin-4-yl-pyrazine-2-carboxylic acid amide 
• 1438419-28-3 3-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-5-((1R,2S)-2-aminocyclohexylamino)pyrazine-2-carboxamide 
• 1935196-58-9 6-chloro-3-iodo-1H-pyrazolo[3,4-b]pyrazine 

Relevant articles and documents

Achieving High 1H Nuclear Hyperpolarization Levels with Long Lifetimes in a Range of Tuberculosis Drug Scaffolds

Despite the successful use of isoniazid, rifampicin, pyrazinamide and ethambutol in the treatment of tuberculosis (TB), it is a disease of growing global concern. We illustrate here a series of methods that will dramatically improve the magnetic resonance imaging (MRI) detectability of nineteen TB-relevant agents. We note that the future probing of their uptake and distribution in vivo would be expected to significantly enhance their efficacy in disease treatment. This improvement in detectability is achieved by use of the parahydrogen based SABRE protocol in conjunction with the 2H-labelling of key sites within their molecular structures and the 2H-labelling of the magnetization transfer catalyst. The T1 relaxation times and polarization levels of these agents are quantified under test conditions to produce a protocol to identify structurally optimized motifs for future detection. For example, deuteration of the 6-position of a pyrazinamide analogue leads to a structural form that exhibits T1 values of 144.5 s for 5-H with up to 20 % polarization. This represents a >7-fold extension in relaxation time and almost 10-fold improvement in polarization level when compared to its unoptimized structure.

UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF

The present application is directed to compounds of Formula (I), (II), (III) or (IV) compositions comprising these compounds, methods for their preparation and their uses, for example, as acyl hydrazone linkers, which can link two chemical entities together for further use as medicaments and/or diagnostics.

SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.